Last $72.03 USD
Change Today +0.56 / 0.79%
Volume 377.0
SHPGF On Other Exchanges
Symbol
Exchange
SHPGF is not on other exchanges.
As of 5:20 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHPGF) Snapshot

Open
$72.02
Previous Close
$71.47
Day High
$72.03
Day Low
$72.02
52 Week High
09/29/14 - $87.45
52 Week Low
12/19/13 - $45.65
Market Cap
42.5B
Average Volume 10 Days
2.2K
EPS TTM
--
Shares Outstanding
590.0M
EX-Date
09/3/14
P/E TM
--
Dividend
$13.30
Dividend Yield
0.29%
Current Stock Chart for SHIRE PLC (SHPGF)

shire plc (SHPGF) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc (SHPGF) Top Compensated Officers

Managing Director, Chief Executive Officer an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc (SHPGF) Key Developments

Shire Reportedly Eyes NPS And Other Targets

Shire plc (LSE:SHP) intends to acquire NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP). Shire is considering an offer for NPS, Bloomberg reported, citing people familiar with the matter. The timing of a possible bid would depend on whether the U.S. Food and Drug Administration approve NPS's Natpara, two of the people told Bloomberg. Shire is seeking other targets as well, Bloomberg said. Reuters added that Shire and NPS were not immediately available for comment. Shares of Shire rose 1.3% while that of NPS rose 23% to $37.5.

Brower Piven Announces Class Action Lawsuit Against Shire plc

Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of Shire plc American Depository Shares or purchased call options or sold put options of Shire between June 20, 2014 and October 14, 2014, inclusive. The complaint accuses AbbVie Inc. and its Chief Executive Officer of violations of the Securities Exchange Act of 1934 by virtue of the Defendants’ failure to disclose during the Class Period that tax considerations were the critical, if not the sole factors for AbbVie’s decision to enter into a proposed business combination of Shire plc and AbbVie whereby AbbVie would merge with and into Shire, with AbbVie as the surviving entity, which would reincorporate in Ireland. According to the complaint, following the U.S. Department of Treasury announcement of a change with respect to the treatment of tax inversions and AbbVie’s subsequent announcement on October 14, 2014 that it was reconsidering the Combination, the value of Shire shares declined substantially.

Shire And AstraZeneca Mulls Acquisition Of Ariad

Shire plc (LSE:SHP) and AstraZeneca PLC (LSE:AZN) are rumored to acquire Ariad Pharmaceuticals Inc. (NasdaqGS:ARIA). Shire and AstraZeneca are stalking Ariad and an auction could ensue. Shares of Ariad closed at $7.38, Astra Zeneca at £46.74 and Shire at £45.63.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPGF:US $72.03 USD +0.56

SHPGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $212.63 USD +0.45
Astellas Pharma Inc ¥1,703 JPY +47.50
CSL Ltd A$86.36 AUD +1.08
Mylan Inc/PA $57.51 USD +0.68
Valeant Pharmaceuticals International Inc C$165.46 CAD -0.32
View Industry Companies
 

Industry Analysis

SHPGF

Industry Average

Valuation SHPGF Industry Range
Price/Earnings 22.9x
Price/Sales 7.3x
Price/Book 6.4x
Price/Cash Flow 32.4x
TEV/Sales 7.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.